Roxadustat and thyroid-stimulating hormone suppression-Reference-Cited by-同舟云学术

Roxadustat and thyroid-stimulating hormone suppression

Published:2021-01-20 Issue:5 Volume:14 Page:1472-1474
ISSN:2048-8513
Container-title:Clinical Kidney Journal
language:en
Short-container-title:

Author:

Tokuyama Atsuyuki¹,Kadoya Hiroyuki¹,Obata Atsushi²³,Obata Takahiro³,Sasaki Tamaki¹,Kashihara Naoki¹

Affiliation:

1. Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan

2. Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Okayama, Japan

3. Obata Medical Clinic, Tsuyama, Okayama, Japan

Abstract

Abstract Hypoxia-inducible factor prolyl-hydroxylase inhibitors belong to a new class of orally administered drugs for treating anemia in patients with chronic kidney disease (CKD). The prevalence of hypothyroidism is disproportionately high in patients with CKD on hemodialysis. We report a rapid suppression of thyroid-stimulating hormone (TSH) and decrease in free triiodothyronine (T3) and free tetraiodothyronine levels after switching from darbepoetin alfa to roxadustat in a hemodialysis patient with hypothyroidism on levothyroxine therapy. This was reversed after stopping roxadustat. Roxadustat has structural similarity with T3 and is a selective activating ligand for thyroid hormone receptor-β possibly suppressing TSH release.

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

Link

http://academic.oup.com/ckj/advance-article-pdf/doi/10.1093/ckj/sfab007/36780911/sfab007.pdf

Reference5 articles.

1. Anaemia management and mortality risk in chronic kidney disease;Horl;Nat Rev Nephrol,2013

2. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients;Besarab;Nephrol Dial Transplant,2015

3. Central hypothyroidism associated with retinoid X receptor-selective ligands;Sherman;N Engl J Med,1999

4. Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance;Yao;iScience,2019

5. Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity;Hoppe;Proc Natl Acad Sci USA,2016

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cerebral Infarction After Switching From Roxadustat to Daprodustat in a Patient With Renal Anemia;Cureus;2024-07-06

2. Association between roxadustat use and suppression of thyroid function: a systematic review and meta-analysis;Journal of Pharmaceutical Health Care and Sciences;2024-06-08

3. Roxadustat-Induced Central Hypothyroidism in Renal Anemia Patients: Insights From Antineutrophil Cytoplasmic Antibody-Related Vasculitis Cases;Cureus;2024-06-06

4. A Prospective Randomized Controlled Clinical Study to Investigate the Efficacy and Safety of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia Switched from Continuous Erythropoietin Receptor Activator Treatment;Journal of Clinical Medicine;2024-05-08

5. Roxadustat and transfusional iron overload induced hypothyroidism in a hemodialysis patient: a case report with a literature review;Renal Replacement Therapy;2024-03-26